Suppr超能文献

他唑巴坦/哌拉西林或他唑巴坦的生殖与发育毒性研究(2)——大鼠静脉给药的致畸学研究

[Reproductive and developmental toxicity studies of tazobactam/piperacillin or tazobactam (2)--Teratological study in rats with intravenously administration].

作者信息

Sato T, Lochry E A, Hoberman A M, Christian M S

机构信息

Drug Safety Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, Japan.

出版信息

J Toxicol Sci. 1994 Oct;19 Suppl 2:215-32. doi: 10.2131/jts.19.supplementii_215.

Abstract

Tazobactam (TAZ) is a newly developed beta-lactamase inhibitor and piperacillin (PIPC) is an antibiotics which is used in clinical field widely. The combination of TAZ and PIPC (TAZ/PIPC), which is combined with TAZ and PIPC at rate of 1:4, has been developed because of PIPC is unstable to various beta-lactamases. Teratogenic potential were studied in rats given daily intravenous doses of TAZ/PIPC (625, 1250, 2500 or 3750 mg/kg/day) or TAZ (125, 500 or 3000 mg/kg/day). TAZ/PIPC or TAZ were given from day 7 to day 17 of pregnancy. Total daily doses were administered in two equally divided doses. The study includes postnatal evaluation of the growth and development and reproductive performance of the F1 generation. Maternal deaths occurred in all groups given TAZ/PIPC. The incidence (range of 3 to 6 animals/group) was not dose dependent. Maternal body weight was decreased in rats receiving 3000 mg/kg of TAZ and food consumption was reduced in all drug-treated groups. Slight decreases in fetal body weights were observed at some doses that caused maternal body-weight or food-consumption decreases (2500 or 3750 mg/kg of TAZ/PIPC, 3000 mg/kg of TAZ). But these depressions of fetal body weights were not significant from control data. There were no fetal malformations or variations attributable to the test articles. Postnatal growth and development, behavior and reproductive performance of the F1 generation were not affected by the administration of TAZ/PIPC or TAZ. In conclusion, TAZ/PIPC or TAZ was not teratogenic in the rats. It is seemed that non-observed effect dose levels (NOELs) of TAZ/PIPC and TAZ for dams is less than 625 and 125 mg/kg/day in general toxicity respectively, however, NOELs of TAZ/PIPC is 3750 mg/kg/day or more and that of TAZ is 300 mg/kg/day or more for their offspring under the condition of this study.

摘要

他唑巴坦(TAZ)是一种新开发的β-内酰胺酶抑制剂,哌拉西林(PIPC)是一种在临床领域广泛使用的抗生素。由于PIPC对各种β-内酰胺酶不稳定,因此开发了以1:4的比例将TAZ和PIPC联合使用的他唑巴坦/哌拉西林(TAZ/PIPC)。对每日静脉注射TAZ/PIPC(625、1250、2500或3750毫克/千克/天)或TAZ(125、500或3000毫克/千克/天)的大鼠进行了致畸潜力研究。TAZ/PIPC或TAZ在妊娠第7天至第17天给药。每日总剂量分两次等量给药。该研究包括对F1代生长发育和生殖性能的产后评估。接受TAZ/PIPC的所有组均发生母体死亡。发生率(每组3至6只动物)与剂量无关。接受3000毫克/千克TAZ的大鼠母体体重下降,所有药物治疗组的食物消耗量均减少。在一些导致母体体重或食物消耗量下降的剂量下(2500或3750毫克/千克TAZ/PIPC,3000毫克/千克TAZ),观察到胎儿体重略有下降。但这些胎儿体重下降与对照数据相比并不显著。没有可归因于受试物的胎儿畸形或变异。TAZ/PIPC或TAZ的给药对F1代的产后生长发育、行为和生殖性能没有影响。总之,TAZ/PIPC或TAZ对大鼠没有致畸性。在一般毒性方面,TAZ/PIPC和TAZ对母鼠的未观察到影响剂量水平(NOELs)分别小于625和125毫克/千克/天,然而,在本研究条件下,TAZ/PIPC对其后代的NOELs为3750毫克/千克/天或更高,TAZ为300毫克/千克/天或更高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验